Arkolith/Insider Trading/XLO/Form 4

Gilead Sciences, Inc.

10% OwnerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Apr 3, 2024
Net Buying
Open-Market Buys
$369K
Open-Market Sells
$0
Net Open-Market Flow
$369K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2024Buy(P)485K$0.76$369K7.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 2, 2024Buy(P)3.9M$0.76$3.0M3.9M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-24-008004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Xilio Therapeutics, Inc.

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp